Last reviewed · How we verify
Ketofol equal ratio
Ketofol, an equal ratio drug marketed by Kasr El Aini Hospital, holds a unique position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its distinct formulation, which differentiates it from existing alternatives. The primary risk is the potential for increased competition once the key patent expires in 2028.
At a glance
| Generic name | Ketofol equal ratio |
|---|---|
| Sponsor | Kasr El Aini Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Dexmedetomidine vs Ketofol on Delirium in Children Undergoing Congenital Inguinal Hernia Repair (NA)
- Two Ratios of Propofol-ketamine Admixture for Rapid-sequence Induction Anesthesia for Emergency Laparotomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketofol equal ratio CI brief — competitive landscape report
- Ketofol equal ratio updates RSS · CI watch RSS
- Kasr El Aini Hospital portfolio CI